Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TENX Stock Price Chart Interactive Chart >
TENX Price/Volume Stats
|Current price||$0.14||52-week high||$1.46|
|Prev. close||$0.14||52-week low||$0.08|
|Day high||$0.14||Avg. volume||1,321,880|
|50-day MA||$0.14||Dividend yield||N/A|
|200-day MA||$0.40||Market Cap||6.16M|
Tenax Therapeutics, Inc. (TENX) Company Bio
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.
Most Popular Stories View All
TENX Latest News Stream
|Loading, please wait...|
TENX Latest Social Stream
View Full TENX Social Stream
Latest TENX News From Around the Web
Below are the latest news stories about TENAX THERAPEUTICS INC that investors may wish to consider to help them evaluate TENX as an investment opportunity.
E ratio of -0.20.
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Update on Tenax Tenax Therapeutics, Inc. (NASDAQ:TENX) will delay the start of its Phase III clinical trials for levosimendan and imatinib for the treatment of pulmonary arterial hypertension (PAH) until 2023, pending funding. The share price has been under pressure for some time and there is insufficient capitalization to
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
MORRISVILLE, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announces the presentation of positive data from a study of PH-HFpEF patients being treated with oral levosimendan. The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extens
Tenax Therapeutics Inc (NASDAQ: TENX) is evaluating alternative strategic paths. Roth Capital Partners will support Tenax Therapeutics as its financial advisor in this process. Tenax Therapeutics and its Board of Directors believe the company's current valuation does not accurately reflect the potential value of its clinical-stage pipeline. Tenax Therapeutics is developing two Phase 3 ready assets - TNX-201 (modified release imatinib) for pulmonary arterial hypertension (PAH) and TNX-103 (oral l
MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company is evaluating alternative strategic paths focused on maximizing shareholder value. Roth Capital Partners will support Tenax Therapeutics as its financial advisor in this process. Tenax Therape
TENX Price Returns